phenobarbital + phenytoin + valproic acid

This is a combination of three classic antiepileptic drugs (AEDs): phenobarbital, phenytoin, and valproic acid. Each drug has a distinct mechanism of action and pharmacological profile: - **Phenobarbital** is a barbiturate that enhances GABAergic inhibition by increasing the duration of chloride channel opening at the GABA-A receptor, leading to central nervous system depression and anticonvulsant effects. - **Phenytoin** stabilizes neuronal membranes by selectively inhibiting voltage-gated sodium channels in their inactive state, thereby reducing repetitive firing of action potentials. - **Valproic acid** increases brain concentrations of gamma-aminobutyric acid (GABA) by inhibiting its degradation and also blocks voltage-gated sodium channels and T-type calcium channels. This combination may be used in refractory epilepsy when monotherapy or dual therapy fails. However, it is associated with significant risks for drug-drug interactions due to overlapping metabolic pathways—particularly hepatic enzyme induction/inhibition—and additive CNS depressant effects. The use of all three together is rare in clinical practice due to increased risk for toxicity but may be considered in select cases under specialist supervision[1][5][6].